Allogeneic stem cell transplantation for older advanced MDS patients: Improved survival with young unrelated donor in comparison with HLA-identical siblings

Leukemia

Volumn 27, Issue 3, 2013, Pages 604-609

  Kroger N ^a   Zabelina, T ^a   De Wreede, L ^b   Berger, J ^a   Alchalby, H ^a   Van Biezen, A ^b   Milpied, N ^c   Volin, L ^d   Mohty, M ^e   Leblond, V ^f   Blaise, D ^g   Finke, J ^h   Schaap, N ⁱ   Robin, M ^j   De Witte, T ⁱ  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

allogeneic stem cell transplantation; donor age; donor selection; MDS; unrelated donor

Indexed keywords

HLA ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; UNRELATED DONORS;

ADULT; AGED; DONOR SELECTION; FEMALE; FOLLOW-UP STUDIES; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SIBLINGS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; YOUNG ADULT;

EID: 84875211034     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.210     Document Type: Article

References (15)

1. Anderson JE, Anasetti C, Appelbaum FR, Schoch G, Gooley TA, Hansen JA et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 1996; 93: 59-67.
2. Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R, Dharan B et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99: 1943-1951.
3. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579-585.
4. de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 620-630.
5. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al. for the Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation Group. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLAidentical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836-846.
6. Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010; 28: 405-411.
7. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S et al. Reducedintensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104: 1616-1623.
8. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043-2051.
9. Carreras E, Jimenez M, Gomez-Garca V, de la Camara R, Martn C, Martnez F et al. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 2006; 37: 33-40.
10. Ash RC, Horowitz MM, Gale RP, van Bekkum DW, Casper JT, Gordon-Smith EC et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant 1991; 7: 443-452.
11. Kroger N. Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood 2012; 119: 5632-5639.
12. Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002; 99: 4370-4378.
13. Miller RA. The aging immune system: primer and prospectus. Science 1996; 273: 70-74.
14. Davies SM, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 2000; 96: 4096-4102.
15. Schultz KR, Green GJ, Wensley D, Sargent MA, Magee JF, Spinelli JJ et al. Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood 1994; 84: 3212-3220.